G(Cbz)-acetic acid
Need Assistance?
  • US & Canada:
    +
  • UK: +

G(Cbz)-acetic acid

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
CBZ-Amino Acids
Catalog number
BAT-008565
CAS number
169287-69-8
Molecular Formula
C15H13N5O5
Molecular Weight
343.29
IUPAC Name
2-[6-oxo-2-(phenylmethoxycarbonylamino)-1H-purin-9-yl]acetic acid
Density
1.60±0.1 g/cm3(Predicted)
InChI
InChI=1S/C15H13N5O5/c21-10(22)6-20-8-16-11-12(20)17-14(18-13(11)23)19-15(24)25-7-9-4-2-1-3-5-9/h1-5,8H,6-7H2,(H,21,22)(H2,17,18,19,23,24)
InChI Key
PLQMFGXJLNMTQH-UHFFFAOYSA-N
Canonical SMILES
C1=CC=C(C=C1)COC(=O)NC2=NC3=C(C(=O)N2)N=CN3CC(=O)O
1. Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors
Mariangela Biava, et al. Bioorg Med Chem. 2014 Jan 15;22(2):772-86. doi: 10.1016/j.bmc.2013.12.008. Epub 2013 Dec 18.
We report herein the development, synthesis, physicochemical and pharmacological characterization of a novel class of pharmacodynamic hybrids that selectively inhibit cyclooxygenase-2 (COX-2) isoform and present suitable nitric oxide releasing properties. The replacement of the ester moiety with the amide group gave access to in vivo more stable and active derivatives that highlighted outstanding pharmacological properties. In particular, the glycine derivative proved to be extremely active in suppressing hyperalgesia and edema.
2. Neuro-protective effects of carbamazepine on sleep patterns and head and body shakes in kainic acid-treated rats
Alfonso Alfaro-Rodríguez, et al. Chem Biol Interact. 2009 Aug 14;180(3):376-82. doi: 10.1016/j.cbi.2009.04.007. Epub 2009 May 3.
The aim of this work was to analyze the effect of carbamazepine (CBZ) on sleep patterns and on "head and body shakes" and to determine the role of serotonin (5-HT) in a model of kainic-induced seizures. Thirty male Wistar rats (280-300 g) were used for polygraphic sleep recording. After a basal recording, the rats were allocated into three groups: kainic acid-treated animals (KA; 10 mg/kg; n=10), carbamazepine-treated animals (CBZ; 30 mg/kg; n=10) and animals injected with KA 30 min after pretreatment with CBZ (CBZ+KA; n=10). Polygraphic recordings were performed for 10 h for 3 days, with the exception of the CBZ group, which were observed for 1 day. In order to measure the head and body shakes that occurred over that time, a behavioral assessment was performed in two additional groups of KA (n=10) and CBZ+KA (n=10) animals. After 10 h of behavioral assessment, the rats were sacrificed, and the levels of 5-HT and 5-hydroxy-indol-acetic acid (5-HIAA) were analyzed. We compared these findings with the results from a group of rats without pharmacological intervention (n=10). All of the recordings were performed from 08:00 to 18:00 h. Data analysis: the electrographic parameters, head and body shake counting and monoamine concentrations were analyzed by an ANOVA test. Differences of *p < or = 0.01 and **p < or = 0.001 were considered statistically significant. Our results showed that CBZ exerted a protective effect on sleep pattern alterations induced by KA, which when administered alone caused a complete inhibition of sleep for the first 10 h after administration. Although there was a reduction in the amount of sleep after the administration of KA in CBZ-pretreated animals, sleep inhibition was incomplete. In addition, CBZ decreased the frequency of head and body shakes by 60% as compared to KA. The 5-HT and 5-HIAA levels in the pons were increased in the KA and KA+CBZ groups. Our conclusion is that in addition to decreasing seizure intensity, CBZ facilitates the partial recovery of sleep. These results suggest that CBZ provides neuro-protective effects on sleep and against seizures.
Online Inquiry
Verification code
Inquiry Basket